Biocon Pertuzumab Biosimilar Pebrilzo Gets EU Marketing Approval

Varda Khade - 0 min read

Last Updated: 18th November 2026 - 03:36 pm

Key Takeaways

  • The European Commission has granted marketing authorisation to Biocon's Pebrilzo, a biosimilar of pertuzumab used in HER2-positive breast cancer.
  • Pebrilzo is the first biosimilar to receive EU approval through the European Medicines Agency's new tailored clinical approach.
  • The European approval follows U.S. FDA clearance for Pebrilzo on November 16, 2026.

The European Commission has granted marketing authorisation to Pebrilzo, Biocon's pertuzumab biosimilar for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union.

Biocon announced the approval on November 18, two months after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for the medicine. The CHMP recommendation was adopted on September 17, 2026.

Pebrilzo is the first biosimilar to receive European approval under the EMA's new tailored clinical approach for biosimilars. The agency had earlier identified it as the first biosimilar recommended for approval following that approach.

What Is Biocon's Pertuzumab Biosimilar?

Pebrilzo contains pertuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2, or HER2. The medicine has been approved as a 420 mg concentrate for solution for infusion.

Its reference medicine is Perjeta, which was authorised in the European Union in 2013. EMA's assessment states that Pebrilzo is highly similar to the reference product, with comparable quality, safety and efficacy.

The medicine is approved for use with trastuzumab and chemotherapy in certain patients with HER2-positive early breast cancer, including neoadjuvant and adjuvant treatment.

For metastatic disease, it can be used with trastuzumab and docetaxel in adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not previously received anti-HER2 therapy or chemotherapy for metastatic disease.

EU Approval Follows U.S. FDA Clearance

The European decision follows another regulatory clearance for the same molecule.

On November 16, 2026, the U.S. Food and Drug Administration approved Pebrilzo, known in the U.S. as pertuzumab-qcay, as a biosimilar to Perjeta. Biocon said the product became its fifth oncology biosimilar to receive U.S. FDA approval.

The EU approval means Biocon's pertuzumab biosimilar has now cleared regulatory review in both Europe and the United States.

Commercial availability will not necessarily begin immediately after regulatory approval. Biocon entered into a global settlement and licence agreement with Genentech in October that established licensed launch timelines for the product across several markets.

Under that agreement, Biocon secured an earliest licensed launch date of Q1 calendar year 2027 in the European Union and UK, while the U.S. licensed launch is scheduled from Q3 calendar year 2028.

Biocon said Pebrilzo is now its fifth oncology biosimilar approved in both Europe and the United States, extending its biosimilars portfolio in cancer treatment.

FREE Trading & Demat Account
Open FREE Demat Account with endless opportunities.
  • Flat ₹20 Brokerage
  • Next-gen Trading
  • Advanced Charting
  • Actionable Ideas
+91
''
By proceeding, you agree to our T&Cs*
Mobile No. belongs to
OR
hero_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form